Mood changes and anxiety are possible side effects of GLP-1 receptor agonists
Mass compounding of new medicines weeks after their approvals undermines the public health and the entire drug review and approval framework, Chanse Jones, deputy vice president of media relations for PhRMA, said in a statement
The higher dose is typically used for people who are being treated for obesity
The STEP UP Phase 3b clinical trial, published in The Lancet Diabetes and Endocrinology in 2025, enrolled over 1,400 adults with obesity and without diabetes
Researchers analyze both peptides when examining differences in structure, stability, and laboratory applications
Cell Death Differ 28 , 31993213 (2021)